Skip to content
DataLookout
Menu

NCT04796012

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 19 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 104 words
    • Enrollment closed, study ongoing
    • Site details revised at 7 of 7 sites
  2. Minor Site contacts updated at 2 of 7 sitesv19
  3. Minor Site contacts updated at 1 of 7 sitesv18
  4. Minor Site details revised at 2 of 7 sitesv17
  5. Minor Site details revised at 2 of 7 sitesv16
Show 13 earlier versionsHide 13 earlier versions
  1. Notable Eligibility criteria shortened, about 20 words
    • Site contacts updated at 1 of 7 sites
    v15
  2. Notable Primary and study completion dates: Jan 2025 to Jan 2027
    • Site contacts updated at 6 of 7 sites
    v14
  3. Notable Eligibility criteria revisedv12
  4. Minor Study sites: 6 to 7v11
  5. Minor Site details revised at 1 of 6 sitesv10
  6. Minor Site details revised at 1 of 6 sitesv9
  7. Minor Site details revised at 1 of 6 sitesv8
  8. Minor Study sites: 1 to 6v7
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2023 to Apr 18, 2023
    • Site details revised
    v6
  10. Notable Phase: Phase 2 to Phase 1/2v5 Show 6 more changesShow less
    • Eligibility criteria expanded, about 260 words
    • Enrollment target: 30 to 23
    • Start date: Jan 2023 to Mar 2023
    • Study description expanded, about 89 words
    • Study arms: 1 to 2
    • Study title expanded, about 1 word
  11. Notable Lead sponsor: Matthew Campbell to University of Texas Southwestern Medical Center
    • Primary and study completion dates: Jan 2024 to Jan 2025
    • Start date: Jul 2022 to Jan 2023
    v4
  12. Notable Start date: Jan 2022 to Jul 2022v3
  13. Notable Primary and study completion dates: Jun 2023 to Jan 2024
    • Start date: Jun 2021 to Jan 2022
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with Dose-limiting Toxicities (DLTs)
Timeframe: Beginning of cycle 3, or 30 days after the second cycle has started, whichever is earlier (each cycle is 21 days)
Number of participants with Acute Adverse Events (AEs)
Timeframe: 42 days post treatment.
Number of participants with Serious Adverse Events (SAEs)
Timeframe: 48 months
Objective response rate (ORR)
Timeframe: Up to 18 weeks post treatment

Secondary (3)

Duration of response
Progression-free survival (PFS)
Overall survival (OS)

Arms and interventions

Feasibility Cohort: Patients with relapsed or refractory solid tumorsExperimental

Six (6) participants with relapsed or refractory solid tumor will be enrolled. Atezolizumab will be administered in combination with vincristine, irinotecan, and temozolomide for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.

Rhabdomyosarcoma (RMS) Cohort: Patients with rhabdomyosarcomaExperimental

Seventeen (17) participants with RMS, including the six participants from the Feasibility Cohort, will be enrolled. At least 8 of the RMS participants must have a tumor that expresses the protein PD-L1. Atezolizumab will be administered in combination with vincristine, irinotecan, and temozolomide for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.

Drugs: Atezolizumab, Vincristine, Irinotecan, Temozolomide

Sites

7 sites in 1 country